GlassScriptPhysician profile
Mandy Lynn Corvino
NPI 1659942647
$4,962.17
in general payments reported to CMS, 2019-2025
29 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $325 · 2022: $950 · 2023: $1,360 · 2024: $1,290 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,598 · Education: $89.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,598.02 |
| Education | $89.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $935.92 | 2021-2025 | Interstim, Altaviva |
| Abbvie INC. | $888.76 | 2022-2025 | |
| Astellas Pharma US INC | $579.39 | 2021-2024 | Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $407.72 | 2023-2025 | Gemtesa, Orgovyx |
| Axonics, INC. | $351.84 | 2021-2024 | Axonics |
| Dendreon Pharmaceuticals LLC | $244.83 | 2022-2024 | Provenge |
| Urovant Sciences INC | $239.67 | 2021-2022 | |
| Janssen Biotech, INC. | $224.36 | 2022-2025 | Erleada, Akeega |
| Antares Pharma, INC. | $182.16 | 2021-2025 | Xyosted |
| Tolmar, INC. | $155.33 | 2023-2025 | Eligard, Jatenzo |
| Urogen Pharma, INC. | $108.21 | 2023-2025 | Jelmyto |
| Allergan, INC. | $101.54 | 2022 | |
| Halozyme INC | $78.27 | 2023 | |
| Myovant Sciences INC. | $72.06 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $59.15 | 2022-2023 | Seglentis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $44.23 | 2025 | Illuccix |
| Calyxo, INC. | $31.16 | 2024 | Cvac Aspiration System |
| Procept Biorobotics Corporation | $30.98 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $29.07 | 2025 | Bard Urinary Drainage Bag |
| Immunitybio, INC. | $27.78 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $24.26 | 2021 | |
| 180 Medical, INC. | $24.16 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $19.84 | 2022 | |
| Blue Earth Diagnostics | $19.51 | 2024 | |
| Abc Home Medical Supply, INC. | $19.00 | 2023 | |
| Cumberland Pharmaceuticals, INC. | $16.96 | 2025 | Caldolor |
| Progenics Pharmaceuticals, INC. | $16.43 | 2021 | |
| Convatec INC. | $15.79 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.79 | 2025 | Adstiladrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Corvino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.